Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Humana Inc (NYSE:HUM) on Wednesday, setting a price target of $460, which is approximately 22.02% above the present share price of $376.99.
Wiederhorn expects Humana Inc to post earnings per share (EPS) of $10.12 for the first quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Humana, with an average price target of $475.82.
The analysts price targets range from a high of $500 to a low of $434.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $20.08 billion and a net profit of $0. The company's market cap is $49.89 billion.
According to TipRanks.com, Oppenheimer analyst Michael Wiederhorn is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.9% and a 74.09% success rate.
Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services (NASDAQ:HCSG).. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance benefits. The Healthcare Services segment offer services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics services to other Humana businesses, as well as external health plan members, external health plans, and other employers. The company was founded by David A. Jones, Sr. and Wendell Cherry in 1961 and is headquartered in Louisville, KY.